This week

New semaglutide liver data is landing at EASL — nine months after an approval most people missed.

This week, ahead of the European Association for the Study of the Liver annual congress beginning May 27 in Barcelona, Novo Nordisk announced comprehensive new analyses from the ESSENCE trial for presentation at EASL 2026. The data covers hepatic safety signals, outcomes in menopausal women, and findings from Japanese patient populations — expanding the evidence base around a regulatory moment that most semaglutide coverage overlooked. [BioPharm International reported on the EASL presentations](https://www.biopharminternational.com/view/novo-nordisk-highlights-semaglutide-liver-safety-and-subgroup-data-in-mash-at-easl-2026). In August 2025, the FDA approved semaglutide as the first GLP-1 receptor agonist cleared to treat metabolic dysfunction-associated steatohepatitis — MASH — with moderate-to-advanced liver fibrosis, stages F2 to F3. [AJMC documented the approval](https://www.ajmc.com/view/fda-approves-semaglutide-for-mash-with-fibrosis). The [American Association for the Study of Liver Diseases applauded it publicly](https://www.aasld.org/aasld-applauds-fda-approval-first-glp-1-therapy-mash-expanding-use-popular-weight-loss-drug-liver), calling it the first GLP-1 therapy cleared for a liver disease. Most of the cultural conversation around semaglutide — the shortage debates, the compounding lawsuits, the Ozempic-face discourse, the before-and-after videos — never made room for what was happening in liver disease research. That story now has new evidence behind it.

The actual biology

A GLP-1 receptor agonist that does more in liver tissue than the appetite story captures.

Semaglutide is most often explained through appetite and blood sugar: it mimics glucagon-like peptide-1, a hormone produced after eating that signals fullness to the brain, slows gastric emptying, and modulates glucose-dependent insulin release. That is the weight-loss and diabetes story. The liver story runs through the same receptor in different tissue. Metabolic dysfunction-associated steatohepatitis develops when excess fat accumulation in liver cells triggers an inflammatory response that drives progressive fibrosis. Untreated, fibrosis can advance to cirrhosis, liver failure, and liver cancer. GLP-1 receptors are expressed in liver tissue as well as in the pancreas, brain, and heart. GLP-1 receptor agonism appears to reduce hepatic fat accumulation, attenuate liver-specific inflammatory signaling, and — per the ESSENCE trial interim data — produce measurable reversal of fibrotic liver injury in a clinically meaningful proportion of patients. The precise molecular mechanism is not fully mapped. What the trial documented is the histological outcome: MASH resolution without worsening of fibrosis in 62.9% of semaglutide participants versus 34.3% in the placebo arm. The [PubMed literature trail for semaglutide](https://pubmed.ncbi.nlm.nih.gov/?term=Semaglutide) is where the mechanistic detail across different tissue contexts lives.

What people think

Most people still think semaglutide is a weight-loss drug. The MASH approval is a different conversation.

The public identity of semaglutide is weight loss. Ozempic, Wegovy, the shot, the shortage, the compounding controversy — that is the cultural frame. When Novo Nordisk released the oral Wegovy pill for weight management in January 2026, and ECO 2026 data this May showed early responders achieving an [average of 21.6% body weight loss at 64 weeks](https://www.biospace.com/press-releases/wegovy-pill-delivered-21-6-weight-loss-in-early-responders-and-doubled-mobility-improvement-according-to-new-novo-nordisk-data-at-eco2026) alongside nearly doubled mobility improvement, that story traveled. The MASH indication did not make the same wave. MASH as a name is clinical, unfamiliar, and hard to explain in a short video. But the condition itself is not rare: it is estimated to affect 250 million people globally, including roughly one in three adults living with overweight or obesity. Before the August 2025 semaglutide approval, no drug had been approved to treat it. The MASH story and the weight-loss story are connected biologically — metabolic dysfunction drives both — but they are culturally separate. The ESSENCE trial showed that treating the metabolic condition through GLP-1 receptor agonism simultaneously treated the liver disease. That connection does not surface in most coverage of the weight-loss drug.

What the data actually shows

The ESSENCE trial showed MASH resolution in 63% of patients. The patient population matters for reading that number.

The headline from the ESSENCE trial interim analysis — the evidence that supported the August 2025 FDA approval — is 62.9% versus 34.3%. Those figures represent the rate of MASH resolution without worsening fibrosis in the semaglutide arm versus placebo at 72 weeks. That difference is clinically meaningful. Context matters for interpreting it. The trial enrolled patients with confirmed MASH and fibrosis at stages F2 to F3 — documented moderate-to-advanced liver fibrosis, not people who are metabolically unhealthy without confirmed histological staging. The approval applies within that population boundary. It excludes cirrhosis. The 34.3% placebo rate reflects the fact that MASH can improve with lifestyle modification and weight loss from any cause, even without drug therapy. What the semaglutide arm demonstrated was a clinically significant benefit above those baseline effects. The American Association for the Study of Liver Diseases updated its practice guidance in November 2025 to incorporate semaglutide for MASH therapy, with an analysis [published in Hepatology in May 2026](https://journals.lww.com/hep/fulltext/2026/05000/semaglutide_therapy_for_metabolic.28.aspx). The full ESSENCE trial continues through 2029, when cardiovascular and liver-mortality endpoint data will assess whether histological MASH resolution translates to reduced cirrhosis incidence and liver-related deaths at the patient outcome level.

Approved medicine

The MASH approval is real and specific — and the EASL data this week is beginning to show how far it reaches.

Semaglutide carries the Approved evidence tier on PeptideFactCheck, which means regulatory certainty for labeled uses — not a blank check for every claim attached to the drug name. The MASH approval adds a third labeled indication alongside type 2 diabetes and chronic weight management, and it carries specific patient-population boundaries. People using semaglutide for weight loss are not automatically treating liver disease through the mechanism the MASH trial evaluated, even if metabolic improvement is occurring simultaneously across systems. People with undiagnosed MASH who begin semaglutide for weight management may be incidentally benefiting from a drug now formally shown to address their liver condition. Both statements can be true at the same time. The EASL 2026 presentations beginning May 27 are filling in what the original approval looks like in subpopulations underrepresented in the ESSENCE trial — menopausal women, Asian patient populations, hepatic safety subgroups. That is how approvals typically broaden: through subsequent analyses and supplemental applications. The 2029 readout will be the next major evidence event for this indication. In May 2026, the MASH approval is nine months old, underreported, and expanding. That is where the evidence actually stands.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.